EUCTR2016-001061-83-ES进行中（未招募）1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML - MORPHO
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject is suitable candidate for HCT and has an acceptable source of allogeneic donor stem cells, as defined per institutional practice (allogeneic HCT for any donor source [matched sibling, unrelated donor (URD), mismatched URD, related haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM, peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be permitted).
- •2.IRB/IEC approved written ICF and privacy language obtained from the participant or legally authorized representative prior to any study-related procedures
- •3.Subject is legal adult by local regulation at the time of signing ICF
- •4.Subject consents to allow access to his or her diagnostic BM aspirate or PB sample and/or the DNA derived from that sample, if available.
- •5.Subject has confirmed, morphologically documented AML in CR1. For the purposes of registration, CR1 will be defined as < 5% blasts in the BM with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
- •a.Subject has not received more than 2 cycles of induction chemotherapy to achieve CR1.
- •b.Subjects with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined as CR with platelet count < 100 x 109/L. Incomplete hematologic recovery (CRi) is defined as CR with residual neutropenia < 1 x 109/L with or without complete platelet recovery. RBC and platelet transfusion independence is not required.
- •c.The maximum time allowed from establishment of CR1 to registration is 12 months.
- •6.Subject has presence of the FLT3/ITD activating mutation in the BM or PB as determined by the local institution at diagnosis.
- •7.Subject must meet the following criteria as indicated on the clinical laboratory tests:
- •a.Serum creatinine within normal range, or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is = 125% of ideal body weight.
- •b.Total bilirubin (TBL) = 2.5 mg/dL, except for participants with Gilbert’s syndrome.
- •c.Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).
- •d.Serum potassium and magnesium greater than the institutional lower limit of normal (LLN).
- •8.Subject has left ventricular ejection fraction at rest = 40%.
- •9.Subject has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) > 50% predicted.
- •For all Registration Inclusion Criteria, see protocol.
- •For a list of Randomization Eligibility Criteria and Randomization Inclusion Criteria, see protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 850
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1.Participant has had a prior allogeneic transplant.
- •2.Participant has Karnofsky performance status score < 70% (APPENDIX F).
- •3.Participant requires treatment with concomitant drugs that are strong inducers of CYP3A4.
- •4.Participant requires treatment with concomitant drugs that target serotonin 5 hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
- •5.Participant has a Fridericia-corrected QT interval (QTcF) > 450 msec (average of triplicate determinations).
- •6.Participant has long QT Syndrome at screening.
- •7.Participant has a known infection with human immunodeficiency virus (HIV) as determined by serology or nucleic acid amplification test (NAAT).
- •8.Participant has active hepatitis B infection as determined by NAAT or surface antigen assay. Participants who have acquired immunity from past exposure (HBcAb positive / HBsAb positive / HBsAg negative) are eligible.
- •9.Participant has active hepatitis C infection as determined by NAAT. Participants who have had past exposure and have no detectable virus either through spontaneous clearance or treatment are eligible.
- •10.Participant with uncontrolled infections will be excluded. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to registration. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to registration.
- •Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
- •Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- •11.Participant has had a myocardial infarction within 6 months prior to registration or New York Heart Association (NYHA) Class III or IV heart failure (APPENDIX D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
- •For all Registration Exclusion Criteria, see protocol.
- •For a list of Randomization Exclusion Criteria, see protocol
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - AMG 785 20062017Acceleration of fracture healingMedDRA version: 12.1Level: LLTClassification code 10043827Term: Tibia fractureEUCTR2008-008392-34-ITAmgen Inc.400
进行中（未招募）
1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT) - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT)Acceleration of fracture healingMedDRA version: 13.1 Level: PT Classification code 10043827 Term: Tibia fracture System Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-GBAmgen Inc400
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo. - RADIANTEUCTR2005-001747-29-ESOSI Pharmaceuticals, Inc.945
进行中（未招募）
不适用
Study of AMG785 in hip fractureAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10016454Term: Femur fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2009-015939-33-BEAmgen Inc330
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine theEfficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Proximal Femur, Status Post Fixation with a Sliding Hip Screw or Intramedullary NailEUCTR2009-015939-33-SEAmgen Inc330